High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party
A recent shortage of melphalan has prompted the use of alternatives to BEAM (BCNU, Etoposide, Cytarabine, Melphalan) conditioning for autologous stem cell transplantion (ASCT). The BEAC (BCNU, Etoposide, Cytarabine, Cyclophosphamide) regimen has been employed as a conditioning regimen in lymphoma pa...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
08 June 2018
|
| In: |
Bone marrow transplantation
Year: 2018, Volume: 53, Issue: 12, Pages: 1553-1559 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/s41409-018-0196-3 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41409-018-0196-3 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41409-018-0196-3 
|
| Author Notes: | Stephen Paul Robinson, Ariane Boumendil, Herve Finel, Peter Dreger, Anna Sureda, Olivier Hermine, Silvia Montoto |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694464156 | ||
| 003 | DE-627 | ||
| 005 | 20220818040021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200414s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-018-0196-3 |2 doi | |
| 035 | |a (DE-627)1694464156 | ||
| 035 | |a (DE-599)KXP1694464156 | ||
| 035 | |a (OCoLC)1341314820 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Robinson, Stephen |e VerfasserIn |0 (DE-588)1192544889 |0 (DE-627)1671096401 |4 aut | |
| 245 | 1 | 0 | |a High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma |b no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party |c Stephen Paul Robinson, Ariane Boumendil, Herve Finel, Peter Dreger, Anna Sureda, Olivier Hermine, Silvia Montoto |
| 264 | 1 | |c 08 June 2018 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.04.2020 | ||
| 520 | |a A recent shortage of melphalan has prompted the use of alternatives to BEAM (BCNU, Etoposide, Cytarabine, Melphalan) conditioning for autologous stem cell transplantion (ASCT). The BEAC (BCNU, Etoposide, Cytarabine, Cyclophosphamide) regimen has been employed as a conditioning regimen in lymphoma patients. However, there have been recent concerns about the toxicity of BEAC. We conducted a retrospective analysis of the EBMT database comparing the outcome of patients conditioned using BEAC with a matched cohort of patients conditioned with BEAM. In the BEAC cohort (n = 383), 25 patients died from non-relapse mortality (NRM) events (32% owing to MOF or cardiac toxicity). In the BEAM cohort (n = 766) there were 34 NRM events (23% owing to MOF or cardiac toxicity). The 1-year cumulative incidence of NRM was 4% in the BEAC cohort and 3% in the BEAM group (p = ns). The 2-year relapse/progression rate was 32% with BEAC and 33% with BEAM (p = ns). At 2 years the progression-free survival (PFS) and overall survival (OS) were 63% and 78% for BEAC and 63% and 77% for BEAM-conditioned patients (p = ns for PFS and OS). The toxicity observed with BEAC conditioning as measured by NRM was similar to that seen with BEAM. The outcomes following BEAC were similar to those seen with BEAM, suggesting that BEAC is a safe conditioning regimen. | ||
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d London : Springer Nature, 1997 |g 53(2018), 12, Seite 1553-1559 |h Online-Ressource |w (DE-627)320433366 |w (DE-600)2004030-1 |w (DE-576)091012996 |x 1476-5365 |7 nnas |a High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party |
| 773 | 1 | 8 | |g volume:53 |g year:2018 |g number:12 |g pages:1553-1559 |g extent:7 |a High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41409-018-0196-3 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41409-018-0196-3 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200414 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 999 | |a KXP-PPN1694464156 |e 3622978317 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma","subtitle":"no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party","title_sort":"High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma"}],"physDesc":[{"extent":"7 S."}],"person":[{"role":"aut","display":"Robinson, Stephen","given":"Stephen","roleDisplay":"VerfasserIn","family":"Robinson"},{"given":"Peter","roleDisplay":"VerfasserIn","family":"Dreger","role":"aut","display":"Dreger, Peter"}],"relHost":[{"recId":"320433366","type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working PartyBone marrow transplantation","origin":[{"publisher":"Springer Nature ; Macmillan ; Nature Publishing Group","dateIssuedDisp":"1997-","publisherPlace":"London ; Basingstoke ; London","dateIssuedKey":"1997"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Bone marrow transplantation","title":"Bone marrow transplantation"}],"part":{"pages":"1553-1559","extent":"7","year":"2018","volume":"53","text":"53(2018), 12, Seite 1553-1559","issue":"12"},"language":["eng"],"id":{"issn":["1476-5365"],"zdb":["2004030-1"],"eki":["320433366"]},"note":["Gesehen am 17.01.25"],"pubHistory":["Nachgewiesen 19.1997 -"]}],"name":{"displayForm":["Stephen Paul Robinson, Ariane Boumendil, Herve Finel, Peter Dreger, Anna Sureda, Olivier Hermine, Silvia Montoto"]},"note":["Gesehen am 14.04.2020"],"language":["eng"],"id":{"doi":["10.1038/s41409-018-0196-3"],"eki":["1694464156"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1694464156","origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"08 June 2018"}]} | ||
| SRT | |a ROBINSONSTHIGHDOSETH0820 | ||